Annexon Biosciences to Participate in Upcoming September Investor Conferences
Annexon Biosciences (Nasdaq: ANNX) announced that CEO Douglas Love will participate in fireside chats at the Wells Fargo Healthcare Conference on September 3, 2025, and the Cantor Global Healthcare Conference on September 4, 2025. Live webcasts will be available on the company’s website, with replays archived for 30 days. Annexon is developing first-in-kind therapies targeting classical complement-driven neuroinflammation for neuroinflammatory di...
08-27 12:00
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
ANNEXON授予新员工60,000股购股权，行使价为每股2.44美元，分4年归属。该股权激励计划依据纳斯达克上市规则获得批准。ANNEXON专注于开发针对补体介导神经炎症疾病的创新疗法。
08-18 20:05
HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $14 Price Target
HC Wainwright & Co. analyst Ananda Ghosh reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $14 price target.
08-15 21:06
Annexon Q2 EPS $(0.34) Beats $(0.37) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 7.1 percent. This is a 47.83 percent decrease over losses of $(0.23) per share from the same
08-15 04:37
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon公司宣布其在多种疾病治疗领域的关键进展。tanruprubart在GBS治疗中展现出显著疗效，预计于2026年第一季度提交欧洲上市申请，并与FDA讨论在美国的上市路径。vonaprument用于干性AMD的全球III期试验ARCHER II完成患者入组，预计2026年下半年公布关键数据。ANX1502在慢性冷凝集素病中的研究进展良好，计划于2025年底提供概念验证结果。公司拥有2.27亿美元现金支持至2026年第四季度运营。
08-14 20:05
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
Annexon, Inc. announced that its vonaprument (formerly ANX007) has been selected by the European Medicines Agency (EMA) to participate in the Product Development Coordinator (PDC) pilot, aimed at streamlining regulatory interactions and evidence planning. Vonaprument, a first-in-kind antibody fragment targeting C1q in the eye, has the potential to become the first approved treatment for dry age-related macular degeneration (AMD) with geographic a...
08-07 20:30
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
Biopharmaceutical company Annexon, Inc. has successfully completed enrollment for its Phase 3 ARCHER II trial of vonaprument for dry age-related macular degeneration (AMD) with geographic atrophy (GA), surpassing the target of 630 participants. Vonaprument, a novel antibody fragment targeting C1q to protect vision, is set to report pivotal data in the second half of 2026. The trial aims to confirm visual acuity protection and structural benefits ...
07-24 11:00
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
Dr. Lloyd Clark, a retina specialist with 25 years of experience, has been appointed as senior vice president of ophthalmology strategy and innovation at Annexon. ANX007, a novel therapy, has shown significant vision preservation in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). The Phase 3 ARCHER II trial, evaluating ANX007, expects to complete enrollment in Q3 2025, with topline data anticipate...
06-18 20:05
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
ANNEXON, Inc. (Nasdaq: ANNX), a biopharmaceutical company developing novel therapies for complement-mediated neuroinflammatory diseases, announced that CEO Douglas Love will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 8:10 a.m. EST. A live webcast and replay will be available on the company's website. Annexon focuses on targeting C1q to stop neuroinflammation in diseases affecting the body, brain, and eye, addressing ...
05-29 20:05
Annexon Presents Data Highlighting Outcomes With Tanruprubart At 2025 Peripheral Nerve Society Annual Meeting
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient
05-20 04:06